EUVIMEDEUVIMED entdecken
Vergleichsstudie

Ocular Outcomes with Tirzepatide versus Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes

Alexander T Hong, Forest Lin, Jeremy D Keenan, Jay M Stewart

Ophthalmology Retina · 2026-06 · 10 (6) · 625-632

DOI: 10.1016/j.oret.2026.02.002 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Ophthalmology Retina, 2026-06. Verfasst von Alexander T Hong und 3 weiteren Autor:innen. Beteiligte Einrichtung: Keck School of Medicine of University of Southern California, Los Angeles, California. Hauptthemen laut MEDLINE: Tirzepatide, Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Diabetic Retinopathy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Research to Prevent Blindness, All May See Foundation, National Eye Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TirzepatideDiabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsDiabetic RetinopathyHumansRetrospective StudiesFemaleMaleHypoglycemic AgentsMiddle AgedAgedIncretinsBlood Glucose

Stichwörter der Autor:innen

Diabetic retinopathyGLP-1 receptor agonistsNonarteritic anterior ischemic optic neuropathyRetinal complicationsTirzepatide

Substanzen

TirzepatideGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsIncretinsBlood Glucose

Autor:innen und Institutionen

  • Keck School of Medicine of University of Southern California, Los Angeles, California.
  • University of South Florida Health Morsani College of Medicine, Tampa, Florida.
  • Francis I. Proctor Foundation, University of California, San Francisco, San Francisco, California; Department of Ophthalmology, University of California, San Francisco, San Francisco, California.
  • Francis I. Proctor Foundation, University of California, San Francisco, San Francisco, California; Department of Ophthalmology, University of California, San Francisco, San Francisco, California; Department of Ophthalmo…

Förderung

  • Research to Prevent Blindness
  • All May See Foundation
  • National Eye Institute

Zitieren

APA

Hong, A. T., Lin, F., Keenan, J. D., & Stewart, J. M. (2026). Ocular Outcomes with Tirzepatide versus Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes. Ophthalmology Retina, 10(6), 625-632. https://doi.org/10.1016/j.oret.2026.02.002

Vancouver

Hong AT, Lin F, Keenan JD, Stewart JM. Ocular Outcomes with Tirzepatide versus Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes. Ophthalmology Retina. 2026;10(6):625-632. doi:10.1016/j.oret.2026.02.002

BibTeX
@article{Hong2026,
  author = {Hong, Alexander T and Lin, Forest and Keenan, Jeremy D and Stewart, Jay M},
  title = {Ocular Outcomes with Tirzepatide versus Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes},
  journal = {Ophthalmology Retina},
  year = {2026},
  volume = {10},
  number = {6},
  pages = {625--632},
  doi = {10.1016/j.oret.2026.02.002}
}
Kostenlos starten →